Last edition
News about Clinical Trials
Caris Study Shows AI Tool Improves Accuracy in Lung Cancer Diagnosis
Caris Life Sciences finds its GPSai algorithm can identify misdiagnosed lung cancer cases, potentially improving treatment decisions and outcomes through AI-driven molecular profiling.
Clinical Trials | 24/03/2026 | By News Bureau
Pfizer-Valneva Lyme Vaccine Shows Strong Phase-III Efficacy
Pfizer and Valneva’s Lyme disease vaccine candidate showed over 70 percent efficacy in phase-III trials in individuals aged five years and above, with a strong safety profile, as Pfizer prepares for regulatory submissions, marking a key step towards potential approval.
Clinical Trials | 24/03/2026 | By News Bureau
Innovent Doses First Patient in Phase III Trial of Tigulixostat for Gout
Innovent initiates Phase III study of tigulixostat against febuxostat in Chinese gout patients, aiming to deliver improved uric acid control and better safety outcomes.
Clinical Trials | 23/03/2026 | By News Bureau | 130
Harbour BioMed Publishes Positive Phase I Data for HBM9378 in Immunology
Harbour BioMed reports favourable safety and pharmacokinetic profile for HBM9378 in Phase I trial, supporting further development for severe immunological disorders.
Clinical Trials | 23/03/2026 | By News Bureau | 125
Biohaven Completes Enrollment in Phase II Trial of Taldefgrobep for Obesity
Biohaven finishes enrollment in Phase II study of taldefgrobep, a novel therapy targeting fat loss and muscle gain, with topline data expected in the second half of 2026.
Clinical Trials | 21/03/2026 | By News Bureau | 297
Lilly's Retatrutide Shows Strong A1C, Weight Reduction in Phase-III Diabetes Trial
Eli Lilly’s Retatrutide reduced A1C by up to two percent and delivered average weight loss of 36.6 lbs in its phase-III TRANSCEND-T2D-1 trial, with continued weight reduction observed through 40 weeks in type-II diabetes mellitus patients.
Clinical Trials | 20/03/2026 | By News Bureau | 168
Sobi Presents Positive Phase IIa Data for Gamifant in Interferon-Driven Sepsis
Sobi reports encouraging Phase IIa EMBRACE study results showing potential of Gamifant in interferon-gamma-driven sepsis, supporting precision medicine approaches in treating high-risk patients.
Clinical Trials | 19/03/2026 | By News Bureau | 360
GentiBio Doses First Patient in Phase I Trial of Novel Cell Therapy for Type 1 Diabetes
GentiBio initiates Phase I POLARIS trial of GNTI-122, an engineered Treg therapy aimed at preserving insulin production and reducing lifelong insulin dependence in newly diagnosed type 1 diabetes patients.
Clinical Trials | 19/03/2026 | By News Bureau | 160
BioVersys AG receives US Food and Drug Administration nod to include US patients in Phase III BV100 trial targeting drug-resistant pneumonia, marking progress in combating deadly hospital infections globally.
Clinical Trials | 18/03/2026 | By News Bureau | 112
EBGLYSS Achieves Phase-III Success in Children with Moderate-to-Severe Atopic Dermatitis
In phase-III ADorable-1 study, EBGLYSS demonstrated strong efficacy in paediatric atopic dermatitis. The treatment also showed meaningful gains in higher efficacy endpoints and itch relief, alongside a safety profile consistent with previous studies and no reported injection site pain.
Clinical Trials | 17/03/2026 | By Akanki | 107
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy